Diagonal Bio Investor Relations Material
Diagonal Bio AB operates as a biotechnology company in Sweden. The company is focused on the development of drug candidate for treatment of diabetes and obesity, based on its technology for targeting the GLP-1 receptor. The company also develops small molecules for pharmaceutical and diagnostic purposes. It offers DiabNext, which is in Phase II trial for dibenzo-p-dioxin (DCDX)-induced significant reduction in pulmonary hypertension syndrome (PH). The company is based in Lund, Sweden.
Webull vs Robinhood: Which Platform Suits You?
In the competitive world of online trading platforms, Webull and Robinhood have emerged as two of the top choices for investors.
24 Nov 2023
Norway's Sovereign Wealth Fund: Transforming Oil Wealth into Lasting Prosperity
But what makes Norway’s striking of oil so fundamentally different from its worse faring counterparts? The answer is in large part its Norwegian Government Pension fund, and Norges Bank Investment Management
24 Nov 2023
Danaher Business System and Acquisition History
Since the early 1990s, Danaher's management team has transformed a group of under-performing industrial manufacturing companies into a global powerhouse in life sciences and diagnostics.
22 Nov 2023